{
    "clinical_study": {
        "@rank": "77264", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir alone in Period 1, MAALOX (MAL) followed 4 hrs later by Raltegravir in Period 2, Raltegravir followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Raltegravir in Period 4, Raltegravir followed 6 hrs later by MAL in Period 5"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "MAL followed 4 hrs later by Raltegravir in Period 1, Raltegravir followed 4 hrs later by MAL in Period 2, Raltegravir alone in Period 3, MAL followed 6 hrs later by Raltegravir in Period 4, Raltegravir followed 6 hrs later by MAL in Period 5"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir followed 4 hrs later by MAL in Period 1, Raltegravir alone in Period 2, MAL followed 4 hrs later by Raltegravir in Period 3, MAL followed 6 hrs later by Raltegravir in Period 4, Raltegravir followed 6 hrs later by MAL in Period 5"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir alone in Period 1, Raltegravir followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Raltegravir in Period 3, Raltegravir followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Raltegravir in Period 5"
            }, 
            {
                "arm_group_label": "Sequence 5", 
                "arm_group_type": "Experimental", 
                "description": "MAL followed 4 hrs later by Raltegravir in Period 1, Raltegravir alone in Period 2, Raltegravir followed 4 hrs later by MAL in Period 3, Raltegravir followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Raltegravir in Period 5"
            }, 
            {
                "arm_group_label": "Sequence 6", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Raltegravir in Period 2, Raltegravir alone in Period 3, Raltegravir followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Raltegravir in Period 5"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effect of single doses of a magnesium/aluminum antacid (MAALOX)\n      before or after administration of raltegravir on the pharmacokinetics of raltegravir in\n      human immunodeficiency virus (HIV)-infected participants. The study will consist of Part 1\n      (Periods 1, 2, and 3) and Part 2 (Periods 4 and 5). Each study period will have a duration\n      of \u22652 days, and the study will pause for evaluation of Part 1 pharmacokinetics results\n      before continuing to Part 2. The same participants will participate in Parts 1 and 2. The\n      primary hypothesis being tested (in Part 1) is that raltegravir plasma concentration 12\n      hours after administration (C 12 hrs) will not differ significantly from raltegravir C 12\n      hrs when antacid is administered 4 hours before or 4 hours after raltegravir."
        }, 
        "brief_title": "A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (0518-295)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  On a stable raltegravir dose as part of a stable antiretroviral regimen for \u22651 month\n             before the study\n\n          -  If female, is not pregnant or breast feeding\n\n          -  Body mass index \u226432 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Mentally or physically incapacitated, has significant emotional problems, or history\n             of clinically significant psychiatric disorder within \u226410 years\n\n          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,\n             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major\n             neurological abnormalities or disease (excluding HIV)\n\n          -  History of gastric bypass surgery\n\n          -  History of cancer, except adequately treated non-melanomatous skin carcinoma or\n             carcinoma in situ of the cervix or other malignancies which have been successfully\n             treated \u226510 years before the study\n\n          -  History of chronic diarrhea within \u22643 months before the study\n\n          -  History of significant multiple and/or severe allergies (food, drug, latex), or had\n             an anaphylactic reaction or significant intolerability to drugs or food\n\n          -  Had major surgery or donated or lost \u22651 unit of blood (500 mL) \u22644 weeks before the\n             study\n\n          -  Participated in another investigational trial \u22644 weeks before the study\n\n          -  Taking rifampin or is unable to refrain from the use of 1) any proton pump inhibitor\n             from 2 weeks before and throughout the study, or 2) any histamine H2-blockers,\n             antacids, calcium supplements, or multivitamins from 2 weeks before and throughout\n             the study\n\n          -  Consumes >3 glasses of alcoholic beverages per day\n\n          -  Consumes excessive amounts of caffeine beverages (coffee, tea, cola, energy drinks,\n             or other caffeinated drinks) per day\n\n          -  Currently uses or has a history of drug abuse within \u22646 months before the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930045", 
            "org_study_id": "0518-295"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 5", 
                    "Sequence 6"
                ], 
                "description": "Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.", 
                "intervention_name": "Raltegravir (ISENTRESS\u2122)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 5", 
                    "Sequence 6"
                ], 
                "description": "MAL (or generic equivalent) 20 mL oral single dose on Day 1", 
                "intervention_name": "MAALOX (MAL)", 
                "intervention_type": "Drug", 
                "other_name": "MAALOX\u00ae MS"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aluminum hydroxide, magnesium hydroxide, drug combination"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 18, 2014", 
        "number_of_arms": "6", 
        "official_title": "A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma Concentration of Raltegravir (C 12 hrs) in Part 1", 
                "safety_issue": "No", 
                "time_frame": "12 hours after dosing on Day 1 of each period in Part 1"
            }, 
            {
                "measure": "Area Under the Plasma Concentration versus Time Curve of Raltegravir (AUC 0-12 hrs) in Part 1", 
                "safety_issue": "No", 
                "time_frame": "Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing on Day 1 of each period in Part 1"
            }, 
            {
                "measure": "Maximum Plasma Concentration of Raltegravir (C max) in Part 1", 
                "safety_issue": "No", 
                "time_frame": "Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing on Day 1 of each period in Part 1"
            }, 
            {
                "measure": "Plasma Concentration of Raltegravir (C 12 hrs) in Part 2", 
                "safety_issue": "No", 
                "time_frame": "12 hours after raltegravir dosing on Day 1 of each period in Part 2"
            }, 
            {
                "measure": "Area Under the Plasma Concentration versus Time Curve of Raltegravir (AUC 0-12 hrs) in Part 2", 
                "safety_issue": "No", 
                "time_frame": "Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing on Day 1 of each period in Part 2"
            }, 
            {
                "measure": "Maximum Plasma Concentration of Raltegravir (C max) in Part 2", 
                "safety_issue": "No", 
                "time_frame": "Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing on Day 1 of each period in Part 2"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}